{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04578223",
      "OrgStudyIdInfo": {
        "OrgStudyId": "KB/138/217"
      },
      "Organization": {
        "OrgFullName": "Medical University of Warsaw",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension",
      "OfficialTitle": "Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension",
      "Acronym": "PAPAYA"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 5, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "November 30, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 23, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "September 30, 2020",
      "StudyFirstSubmitQCDate": "September 30, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 8, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 8, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 9, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Medical University of Warsaw",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "European Health Centre Otwock",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Background: Prostacyclin analogues (epoprostenol, treprostinil and iloprost) induce vasodilation in advanced pulmonary arterial hypertension (PAH) but also inhibit platelets, increasing patients' bleeding risk. The antiplatelet effects of different prostacyclin analogues have never been compared head-to-head. The goal of the PAPAYA (Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension) trial is(i) to compare platelet function (platelet reactivity, extracellular vesicles concentration and thrombus formation) in patients with PAH treated with prostacyclin analogues on top of endothelin receptor antagonists (ERA) and/or phosphodiesterase type 5 inhibitors (PDE5i) and patients treated only with ERA and PDE5i, and (ii) to compare the antiplatelet effect of different prostacyclin analogues.\n\nVenous blood will be collected from patients treated with prostacyclin analogues (study group; n=40) and patients treated with ERA or PDE5i (control group; n=40). Platelet reactivity will be analysed in whole blood by impedance aggregometry using arachidonic acid, adenosine diphosphate and thrombin receptor-activating peptide as agonists. Concentrations of extracellular vesicles from all platelets (CD61+), activated platelets (CD62P+), leukocytes (CD45+) and endothelial cells (CD146+) will be analysed in platelet-depleted plasma using flow cytometry (A-60 Micro). Platelet-rich thrombus formation will be measured using whole blood perfusion system. The study will determine the antiplatelet effect of prostacyclin analogues and compare different prostacyclin analogues head-to-head to identify the best drugs to use in case of thrombosis or bleeding."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Pulmonary Hypertension"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "prostacyclin analogues",
          "pulmonary arterial hypertension",
          "platelet reactivity",
          "extracellular vesicles",
          "thrombus formation"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Observational",
      "PatientRegistry": "No",
      "DesignInfo": {
        "DesignObservationalModelList": {
          "DesignObservationalModel": [
            "Case-Control"
          ]
        },
        "DesignTimePerspectiveList": {
          "DesignTimePerspective": [
            "Prospective"
          ]
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "80",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Study group",
            "ArmGroupDescription": "Patients with pulmonary arterial hypertension treated with prostacyclin analogues on top of ERA or PDE-5i."
          },
          {
            "ArmGroupLabel": "Control group",
            "ArmGroupDescription": "Patients with pulmonary arterial hypertension treated with ERA or PDE-5i only."
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Platelet reactivity",
            "PrimaryOutcomeDescription": "Difference in platelet reactivity between patients treated with prostacyclin analogues and treated with ERA and/ or PDE5-i, assessed using impedance aggregometry",
            "PrimaryOutcomeTimeFrame": "July 5, 2017 - November 30, 2019"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Concentration of extracellular vesicles from platelets, leukocytes and endothelial cells",
            "SecondaryOutcomeDescription": "Differences in concentration of extracellular vesicles from platelets, leukocytes and endothelial cells between patients treated with prostacyclin analogues and treated with ERA and/ or PDE5i, assessed using flow cytometry",
            "SecondaryOutcomeTimeFrame": "July 5, 2017 - November 30, 2019"
          },
          {
            "SecondaryOutcomeMeasure": "Platelet-rich thrombus formation parameters",
            "SecondaryOutcomeDescription": "Differences in platelet-rich thrombus formation parameters between patients treated with prostacyclin analogues and treated with ERA and/ or PDE5i, assessed using whole-blood flow-chamber perfusion system",
            "SecondaryOutcomeTimeFrame": "July 5, 2017 - November 30, 2019"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nInformed consent to participate in the study\nPulmonary arterial hypertension confirmed with right heart catheterization\nTreatment with prostacyclin analogues (epoprostenol, treprostinil, iloprost) - study group\nTreatment with endothelin receptor antagonists and phosphodiesterase type 5 inhibitors - control group\n\nExclusion Criteria:\n\nKnown coagulopathy\nActive pathological bleeding\nKnown history of bleeding disorder\nSevere thrombocytopenia (platelet count < 50,000/Î¼L )\nNeed for antiplatelet therapy with acetylsalicylic acid or P2Y12 antagonists\nSevere chronic renal failure (estimated glomerular filtration rate < 30 mL/min)\nSevere liver insufficiency (Child-Pugh class C)\nKnown pregnancy, breast-feeding, or intention to become pregnant during the study period\nStudy drug intolerance\nParticipation in any previous study with prostacyclin analogues",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "99 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      },
      "StudyPopulation": "Patients were eligible for enrolment if they (i) had PAH diagnosed according to the criteria of European Society of Cardiology and European Respiratory Society, confirmed during right heart catheterization, (ii) were treated with prostacyclin analogues on top of other drugs (study group) or only other drugs (ERA and PDE-5i; control group) for at least 1 month.",
      "SamplingMethod": "Probability Sample"
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Education Medical, European Health Centre Otwock",
            "LocationCity": "Warsaw",
            "LocationCountry": "Poland"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006976",
            "ConditionMeshTerm": "Hypertension, Pulmonary"
          },
          {
            "ConditionMeshId": "D000081029",
            "ConditionMeshTerm": "Pulmonary Arterial Hypertension"
          },
          {
            "ConditionMeshId": "D000006973",
            "ConditionMeshTerm": "Hypertension"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9176",
            "ConditionBrowseLeafName": "Hypertension",
            "ConditionBrowseLeafAsFound": "Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9179",
            "ConditionBrowseLeafName": "Hypertension, Pulmonary",
            "ConditionBrowseLeafAsFound": "Pulmonary Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15838",
            "ConditionBrowseLeafName": "Thrombosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2262",
            "ConditionBrowseLeafName": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafAsFound": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4807",
            "ConditionBrowseLeafName": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafAsFound": "Pulmonary Arterial Hypertension",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M13480",
            "InterventionBrowseLeafName": "Epoprostenol",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M262308",
            "InterventionBrowseLeafName": "Tezosentan",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "AnAg",
            "InterventionBrowseBranchName": "Antihypertensive Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "PlAggInh",
            "InterventionBrowseBranchName": "Platelet Aggregation Inhibitors"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "VaDiAg",
            "InterventionBrowseBranchName": "Vasodilator Agents"
          }
        ]
      }
    }
  }
}